BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 32352484)

  • 1. Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19.
    Rubin R
    JAMA; 2020 Jun; 323(21):2114-2117. PubMed ID: 32352484
    [No Abstract]   [Full Text] [Related]  

  • 2. The resurgence of convalescent plasma therapy.
    The Lancet Haematology
    Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447
    [No Abstract]   [Full Text] [Related]  

  • 3. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?
    Prajapati S
    Homeopathy; 2020 Aug; 109(3):184-185. PubMed ID: 32645727
    [No Abstract]   [Full Text] [Related]  

  • 4. Convalescent Plasma: Promise for COVID-19 Pandemic.
    Sheikh S; Baig MA
    J Coll Physicians Surg Pak; 2020 Jun; 30(6):88. PubMed ID: 32723468
    [No Abstract]   [Full Text] [Related]  

  • 5. Convalescent plasma is ineffective for covid-19.
    Pathak EB
    BMJ; 2020 Oct; 371():m4072. PubMed ID: 33093025
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence lags behind excitement over blood plasma as a coronavirus treatment.
    Ledford H
    Nature; 2020 Aug; 584(7822):505. PubMed ID: 32820261
    [No Abstract]   [Full Text] [Related]  

  • 7. The convalescent sera option for containing COVID-19.
    Casadevall A; Pirofski LA
    J Clin Invest; 2020 Apr; 130(4):1545-1548. PubMed ID: 32167489
    [No Abstract]   [Full Text] [Related]  

  • 8. Convalescent plasma to treat COVID-19.
    Bloch EM
    Blood; 2020 Aug; 136(6):654-655. PubMed ID: 32761219
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive immunotherapy with convalescent plasma against COVID-19? What about the evidence base and clinical trials?
    Garraud O
    Transfus Apher Sci; 2020 Aug; 59(4):102858. PubMed ID: 32631501
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of COVID-19 Virus Infection by Convalescent Plasma.
    Cheraghali AM; Abolghasemi H; Eshghi P
    Iran J Allergy Asthma Immunol; 2020 May; 19(S1):3-6. PubMed ID: 32534509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of convalescent plasma for COVID-19 treatment. History and evidence].
    McAllister F; Mantegazza A; Garzón F; Rotbaum V; Remondino G; Vazquez Larsson M; Geffner J; Rabinovich GA; Bover L
    Medicina (B Aires); 2020; 80 Suppl 3():82-86. PubMed ID: 32658853
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of COVID-19: old tricks for new challenges.
    Cunningham AC; Goh HP; Koh D
    Crit Care; 2020 Mar; 24(1):91. PubMed ID: 32178711
    [No Abstract]   [Full Text] [Related]  

  • 14. Why should we use convalescent plasma for COVID-19?
    Franchini M
    Eur J Intern Med; 2020 Jul; 77():150-151. PubMed ID: 32425365
    [No Abstract]   [Full Text] [Related]  

  • 15. Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.
    Accorsi P; Berti P; de Angelis V; De Silvestro G; Mascaretti L; Ostuni A;
    Blood Transfus; 2020 May; 18(3):163-166. PubMed ID: 32453687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma for covid-19.
    Estcourt LJ; Roberts DJ
    BMJ; 2020 Sep; 370():m3516. PubMed ID: 32933945
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of Convalescent Plasma Therapy on COVID-19.
    Zhao Q; He Y
    J Clin Virol; 2020 Jun; 127():104358. PubMed ID: 32305026
    [No Abstract]   [Full Text] [Related]  

  • 20. Convalescent Plasma and COVID-19.
    Malani AN; Sherbeck JP; Malani PN
    JAMA; 2020 Aug; 324(5):524. PubMed ID: 32530454
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.